by Nicholas Mitsakos | Artificial Intelligence, Book Chapter, Innovation, Investment Principles, irrationality, Technology, Transformative businesses, Writing and Podcasts
AI is extraordinary. The economics are not.
Artificial intelligence has triggered the largest coordinated capital commitment of the modern technology era. The builders will spend close to $800 billion this year and approach $1 trillion next year on chips, data centers, networks, and power. Total AI revenue this year will be roughly $150 to $200 billion.
AI will reshape the global economy, and much of the capital financing that transformation will be impaired. Revenue, productivity, and cash flow will all arrive, but on the wrong schedule, after much of what was built to capture them has lost its economic value.
We have seen this movie. Railroads. Telephone and wireless networks. Fiber. The commercial internet. Each transformed the economy. Each destroyed the capital of those who built it first. The infrastructure survived. The investors did not.
The question is not whether the AI opportunity is real. The question is who pays for the gap between when the capital is spent and when the value arrives. AI may define this era. The uncertainty is whether today’s owners, creditors, communities, and ratepayers capture enough of its value to justify what they’re building with their capital.
by Nicholas Mitsakos | AI Agents, Artificial Intelligence, Biotechnology, drug discovery, Public Policy, Technology, Transformative businesses, Writing and Podcasts
Must the AI frontier slow down? Perhaps. But that is not the right question. We should ask what, precisely, must slow; what risk that restraint would reduce; who could enforce it; and what would happen if careful firms paused while less careful actors did not.
Dario Amodei has published one of the most consequential essays yet written by a frontier AI company leader. He is candid, and he is reconsidering an earlier, more benign, position. But his argument is flawed: a model’s capability is not an application or an outcome.
He says the latest models can offer dramatically good or dramatically bad outcomes. On the one hand, AI may cure most major diseases within five to ten years. But it may also become an agent swarm capable of seizing the internet within six to twelve months.
Both are wrong. These extremes are oversimplifications and can undermine both AI’s benefits in many areas and our ability to regulate and monitor it appropriately. Simply saying “boo” and hoping everyone else is frightened isn’t an effective, comprehensive strategy for addressing a serious issue.
Any good or bad from an AI model only appears when that model is part of a system that enters the world through software, capital, organizations, machines, biological systems, and public institutions. Understanding this lets us unleash AI’s potential for good while also building the systems and processes to protect society.
by Nicholas Mitsakos | Artificial Intelligence, Book, Innovation, Technology, Transformative businesses, Writing and Podcasts
We are told that we have entered an unprecedented era. Perhaps. The more useful response is to step back. Perspective does not diminish technological achievement. It allows us to distinguish engineering from magic, capability from consequence, and a genuine inflection point from a fashionable narrative. This book is about that distinction.
Artificial intelligence is a powerful tool that can make tools. But capability is not destiny. Its value and its danger emerge only when it enters real systems: energy, software, capital, organizations, machines, biology, and political institutions.
by Nicholas Mitsakos | AI Agents, Artificial Intelligence, Human learning, Innovation, Technology, Training, Transformative businesses, Writing and Podcasts
The future of AI will be systems that enter an environment, build memories, recognize gaps, ask questions, conduct experiments, model consequences, learn from people, and revise themselves under controlled conditions. AI will become an experiential learning tool. This transition would reduce dependence on internet-scale data, redistribute competitive advantage, accelerate robotics and autonomous science, strengthen specialized and sovereign AI, and create entirely new governance challenges. The next great advance in artificial intelligence may not be a machine trained on everything. It may be a machine that knows how to learn what matters.
by Nicholas Mitsakos | AI Agents, Artificial Intelligence, Biotechnology, Book Chapter, crispr, drug discovery, Health Care, Transformative businesses, Writing and Podcasts
AI cures disease only if the cures already are within a set we have measured, waiting for a better approach. One problem: they do not. Most of human biology has never been observed with detail and understanding sufficient to target a therapy. No amount of inference recovers data that was never collected. The need for AI in life sciences and drug discovery is indisputable. Of roughly ten thousand known human diseases, the large majority have no approved therapy at all; among rare diseases, the figure approaches ninety-five percent. Most approved drugs slow a disease rather than stop it. For the bulk of human illness, medicine offers management or nothing. Humans are systems, and the hardest diseases are within human systems and unsolved. The constraint is not intelligence. It is understanding the system.
by Nicholas Mitsakos | Artificial Intelligence, Biotechnology, Book, China, drug discovery, energy, Globalization, Innovation, Physical Intelligence, Robotics, Science, space, Technology, Transformative businesses, Writing and Podcasts
Technological, geopolitical, and capital transformation are interconnected, with unprecedented impacts on a globally connected, directly entangled economic and geopolitical world. Choices are simultaneously investment decisions, national security decisions, and civilizational bets on which technological architecture will define the next century.
Understanding them requires insightful economic, strategic, and institutional thinking. More than ever, it requires intellectual courage and patience with complexity.
by Nicholas Mitsakos | Artificial Intelligence, Book Chapter, Innovation, Writing and Podcasts
AI and real-world visual understanding remain unsolved. Machines can recognize a face, caption a photograph, describe a scene, and outperform radiologists on narrow diagnostic tasks. So, if machines can see what we see, they must be doing what we do. They don’t. Nature does not produce straight lines, perfect circles, or right angles. AI lacks comprehensive human visual reasoning.
by Nicholas Mitsakos | Artificial Intelligence, Biotechnology, Book Chapter, Health Care, Innovation, Science, Transformative businesses, Writing and Podcasts
Artificial intelligence is no longer a tool that the life sciences industry is adopting. It is a force that is relocating where value is created and who captures it. Three costs are collapsing at once: drug discovery, company independence, and the ability to reach the patient. Each of these costs was, for forty years, a moat protecting the incumbents who could afford to pay it. In addition, the capacity to discover and manufacture medicine has become a strategic infrastructure in the same category as energy, semiconductors, and compute. The molecule has become computable. The architecture of value creation in life sciences has changed.
by Nicholas Mitsakos | Artificial Intelligence, Biotechnology, Book Chapter, drug discovery, Health Care, Innovation, software, Writing and Podcasts
Artificial intelligence is reducing the time and cost required to discover new drug candidates. New forms of late-stage capital are allowing better companies to stay independent longer. Direct-to-patient distribution is weakening Pharma’s control of the commercial channel. Together, these changes alter the architecture of biotechnology. The molecule is being separated from the old machine that used to deliver it. This is a structural change in how drugs are discovered, financed, developed, negotiated, and delivered. Biotech companies will build discovery systems, develop clinical evidence, control proprietary data, preserve financing options, and reach patients more directly.
